Souhaitez-vous accéder aux communiqués récents ?

Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

JASPER, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- German American Bancorp, Inc. (Nasdaq: GABC) reported first quarter 2024 earnings of $19.0 million, or $0.64 per share, compared to earnings of $21.5...

Zurich, Switzerland , April 29, 2024 (GLOBE NEWSWIRE) -- Mooner Hive, the premier platform for newly launched cryptocurrency token listings and crypto earnings, is revolutionizing the way investors...

MUNSTER, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NorthShore Health Centers and Obstetrical & Gynecological Associates have merged to create a more comprehensive healthcare experience for...

Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...

FREMONT, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery...

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006

Cityview has completed Belle on Bev – a 243-unit mixed-use project in Los Angeles’ Historic Filipinotown

Les nouvelles données immunologiques de Phase I confirment la forte immunogénicité de TG4050 dans le traitement adjuvant des cancers de la tête et du cou.Tous les patients traités sont encore en...

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...